Artwork

Innhold levert av John Bellone and Ryan Van Patten - NavNeuro. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av John Bellone and Ryan Van Patten - NavNeuro eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

135| Neuropsychology’s Role in Anti-Amyloid Therapies – A Conversation With Dr. Kevin Duff

31:00
 
Del
 

Manage episode 395482013 series 2422086
Innhold levert av John Bellone and Ryan Van Patten - NavNeuro. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av John Bellone and Ryan Van Patten - NavNeuro eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Today we give you a discussion with Dr. Kevin Duff about neuropsychologists’ role with respect to lecanemab and other antiamyloid therapies.

Show notes are available at www.NavNeuro.com/135

_________________

If you’d like to support the show, here are a few easy ways:

1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS

2) Tell your friends and colleagues about it

3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes

4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating

Thanks for listening, and join us next time as we continue to navigate the brain and behavior!

[Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

  continue reading

151 episoder

Artwork
iconDel
 
Manage episode 395482013 series 2422086
Innhold levert av John Bellone and Ryan Van Patten - NavNeuro. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av John Bellone and Ryan Van Patten - NavNeuro eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Today we give you a discussion with Dr. Kevin Duff about neuropsychologists’ role with respect to lecanemab and other antiamyloid therapies.

Show notes are available at www.NavNeuro.com/135

_________________

If you’d like to support the show, here are a few easy ways:

1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS

2) Tell your friends and colleagues about it

3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes

4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating

Thanks for listening, and join us next time as we continue to navigate the brain and behavior!

[Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

  continue reading

151 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett